Progress and potential for gene-based medicines.
During the past decade researchers have explored the potential of gene-based medicines to extend current treatments employing chemical entities and proteins. However, progress has been slower than was originally predicted due to our limited knowledge of the genetic components of major diseases, the complexity of developing active biological agents as therapies, and the stringent and time-consuming tests necessary to ensure safety prior to introduction of these novel modalities in the clinic. In spite of the present technology challenges and clinical setbacks in gene therapy it is anticipated that gene-based medicines will find their niche in disease prevention and management strategies in the coming decade, extending the repertoire of medicines available to satisfy key unmet medical needs. Additionally, progress in xenotransplantation research is creating the opportunity to use gene-modified porcine organs for human transplantation. This innovative approach aims to address the current insufficiency of human donor organs for clinical transplantation.
Novartis Pharma AG, Basel, Switzerland.
M R
MR
Dyer
P L
PL
Herrling
D000818:Animals; D001675:Bioethics; D002986:Clinical Trials as Topic; D004279:DNA, Viral / Q000235:genetics; D005786:Gene Expression Regulation; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000096:biosynthesis; D006801:Humans; D016377:Organ Transplantation; D012367:RNA, Viral / Q000235:genetics; D014183:Transplantation, Heterologous
D004279:DNA, Viral; D012367:RNA, Viral